PolyMedix Has Regulatory Clearance To Initiate Phase I Clinical Study Of Novel Anticoagulant Antagonist Compound

�PolyMedix, Inc. (OTC BB: PYMX), an emerging biotech company development new sanative drug products to e complete description of these risks, uncertainties and assumptions is included in PolyMedix's filings with the Securities and Exchange Commission. You should not